Kyverna Therapeutics, Inc. Contracts & Agreements
23 Contracts & Agreements
- Business Finance (5 contracts)
- Business Operations (2)
- Human Resources (11)
- Intellectual Property (2)
- Real Estate (2)
- Uncategorized (1)
- Kyverna Therapeutics, Inc. 2024 Inducement Equity Incentive Plan (Filed With SEC on September 16, 2024)
- Separation and General Release Agreement, dated September 13, 2024, between Kyverna Therapeutics, Inc. and Peter Maag, Ph.D (Filed With SEC on September 16, 2024)
- Employment Offer Letter, dated September 14, 2024, between Kyverna Therapeutics, Inc. and Warner Biddle (Filed With SEC on September 16, 2024)
- Description of Registrants Securities (Filed With SEC on March 26, 2024)
- Kyverna Therapeutics, Inc. 2024 Equity Incentive Plan Form of Restricted Stock Unit Award Agreement (Filed With SEC on February 6, 2024)
- Form of Underwriting Agreement (Filed With SEC on February 1, 2024)
- Kyverna Therapeutics, Inc. Non-Employee Director Compensation Program (Filed With SEC on February 1, 2024)
- Form of Indemnification Agreement (Filed With SEC on February 1, 2024)
- Kyverna Therapeutics, Inc. 2024 Employee Stock Purchase Plan (Filed With SEC on February 1, 2024)
- Kyverna Therapeutics, Inc. 2024 Equity Incentive Plan Form of Restricted Stock Unit Award Agreement (Filed With SEC on February 1, 2024)
- Kyverna Therapeutics, Inc. 2024 Equity Incentive Plan Form of Stock Option Agreement (Filed With SEC on February 1, 2024)
- Kyverna Therapeutics, Inc. 2024 Equity Incentive Plan (Filed With SEC on February 1, 2024)
- Form of Common Stock Certificate (Filed With SEC on January 16, 2024)
- Patent License Agreement (License Number L-159-2021-0), dated May 27, 2021, between Kyverna Therapeutics, Inc. and the National Institutes of Health (Filed With SEC on January 16, 2024)
- Patent License Agreement (License Number L-158-2021-0), dated May 20, 2021, between Kyverna Therapeutics, Inc. and the National Institutes of Health (Filed With SEC on January 16, 2024)
- License and Collaboration Agreement, dated December 29, 2021, between Kyverna Therapeutics, Inc. and Intellia Therapeutics, Inc (Filed With SEC on January 16, 2024)
- First Amendment to Office/Laboratory Lease, dated November 29, 2021, between Kyverna Therapeutics, Inc. and Emery Station Office II, LLC (Filed With SEC on January 16, 2024)
- Office/Laboratory Lease, dated July 21, 2020, between Kyverna Therapeutics, Inc. and Emery Station Office II, LLC (Filed With SEC on January 16, 2024)
- Amended and Restated Investors Rights Agreement, dated November 9, 2021 (Filed With SEC on January 16, 2024)
- Employment Offer Letter, dated July 9, 2021, between Kyverna Therapeutics, Inc. and Karen Walker (Filed With SEC on January 16, 2024)
- Employment Offer Letter, dated March 23, 2021, between Kyverna Therapeutics, Inc. and James Chung, M.D., Ph.D (Filed With SEC on January 16, 2024)
- Employment Offer Letter, dated October 4, 2022, between Kyverna Therapeutics, Inc. and Peter Maag, Ph.D (Filed With SEC on January 16, 2024)
- Kyverna Therapeutics, Inc. Amended and Restated 2019 Stock Plan, as amended, and forms of agreement thereunder (Filed With SEC on January 16, 2024)
